skip to content
Primary navigation

Abilify Maintena

Drug - Abilify Maintena™ (aripiprazole) [Otsuka America Pharmaceutical, Inc.]

August 2017

Therapeutic area - mental health

Approval criteria

  • Patient has a diagnosis of schizophrenia OR bipolar I disorder AND
  • Patient is 18 years of age or older AND
  • Patient has shown a favorable response to oral aripiprazole (Abilify) in efficacy measures AND
  • Patient has demonstrated poor compliance (> 30% missed doses) with oral aripriprazole (Abilify) OR
  • Patient has been stabilized on Abilify Maintena (the drug is part of the patient’s current course of treatment) as covered on a previous health insurance plan, and patient is new to MA OR
  • Patient was started and stabilized on Abilify Maintena in an acute care setting, such as during a hospitalization, or within another place of care that offers acute care services.


Abilify Maintena is not covered through the MHCP fee-for-service pharmacy benefit and must be submitted as a medical claim.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top